|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase I and pharmacokineticstudy of ABI- 007,a cremophorfree,protein-stabilized,nanoparticleformulation of paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 2 | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab,paclitaxel,and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer显示文摘 | Buzdar AU Ibrahim NK Francis D | 2005 | J Clin Onco12005，23，16： | 1 |
| 3 | Phase I and pharmaeokinetic study of ABI - 007, a Cremophor - free, protein - stabilized, nanoparticle formulation of paclitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clinical Cancer Res2002，8，： | 1 |
| 4 | Phase Ⅰ and pharmacokinetic study of ABI-007, a Cremophor-free, protein- stabilized, nanoparticle formulation of paclitaxel显示文摘 | IBRAHIM NK DESAI N LEGHA S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 5 | Multicenter phaseⅡtrial of ABI-007,an albumin-bound paclitaxel,in women with metastatic breast cancer显示文摘 | Ibrahim NK Samuels B Page R | 2005 | Journal of Clinical Oncology2005，23，25： | 1 |
| 6 | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab,paclitaxel,and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer显示文摘 | Buzdar AU Ibrahim NK Francis D | 2005 | J Clin Oncol2005，23，16： | 1 |
| 7 | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, pachtaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor recptor 2-positive operable breast cancer 显示文摘 | Buzdar AU Ibrahim NK Francis D | 2005 | Chn Oncol2005，23，16： | 1 |
| 8 | Neoadjuvant therapy with paclitaxel followed by 5fluorouracil, epirubicin, and cyclo- phosphamide chemotherapy and concmTent trastuzumab in human epidermal growth factor receptor 2positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen显示文摘 | Buzdar AU Valero V Ibrahim NK et at | 2007 | Clin Canc- er Res2007，13，1： | 1 |
| 9 | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2 positive operable breast cancer显示文摘 | Buzdar AU Ibrahim NK Francis D | 2005 | J Clin Oncol2005，23，16： | 1 |
| 10 | Significantly higher pathologic complete remission rate after neoadju- rant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer显示文摘 | Buzdar AU Ibrahim NK Francis D | 2005 | J Clin Oncol2005，23，16： | 1 |
| 11 | Phase I and pharmaco- kinetic study of ABI-007, a Cremophor-free proteinstabilized, nanoparticle formulation of paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 12 | Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer显示文摘 | Ibrahim NK Valero V Theriault RL | 2000 | American Journal of Clinical Oncology2000，23，2： | 1 |
| 13 | Phase Ⅰ study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer 显示文摘 | Ibrahim NK Rahman Z Valero V | 2002 | Cancer Invest2002，20，1： | 1 |
| 14 | Phase I and pharmaeo - ki- netic study of ABI - 007, a Cremophor - free, protein - stabilized, nanoparticle formulation of paelitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Cliii Cancer Res2002，8，： | 1 |
| 15 | A new minimally invasive technique to show nen' e I schaemia in diabetic neuropathy显示文摘 | Ibrahim NK Harris M Radata | 1999 | Diabeto logian1999，，42： | 1 |
| 16 | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab,paclitaxeel,and epirubicin chemotherapy:results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer显示文摘 | Buzdar AU Ibrahim NK Francis D | | 0，，： | 1 |
| 17 | Phase Ⅰ and pharmacokinetic study of ABI-007,a cremophor-free,protein-stabilized,nanoparticle formulation of paclitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 18 | Medical students preference of problem-based learning or traditional lectures in King Abdulaziz University, Jeddah, Saudi Arabia显示文摘 | Ibrahim NK Banjar S A1-Ghamdi A | 2014 | Ann Saudi Med2014，34，2： | 1 |
| 19 | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer显示文摘 | Buzdar AU Ibrahim NK Francis D | 2005 | J Clin Oncol2005，23，16： | 1 |
| 20 | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy : results of a randomized trial in human epidermal growth factor receptor 2- positive operable breast cancer 显示文摘 | Buzdar AU Ibrahim NK Francis D | 2005 | J Clin Oncol2005，23，16： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员